Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
US10927170B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 15, 2018 |
| Grant date | Feb 23, 2021 |
| Priority date | — |
| Expiry date | May 15, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.